(Q39174229)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

title

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

5 April 2020

main subject

phase III clinical trial

0 references

0 references

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

James Ford

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Paolo Antonio Ascierto

object named as

Paolo A Ascierto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Keith Flaherty

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

David Hogg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Caroline Dutriaux

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Paola Queirolo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Gabriella Liszkay

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Michele Del Vecchio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Ralf Gutzmer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Mario Mandala

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Dirk Schadendorf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Reinhard Dummer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

author name string

Anna Maria Di Giacomo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Lev Demidov

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Ernesto Wasserman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Marine Weill

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

L Andres Sirulnik

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Valentine Jehl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Viviana Bozón

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

publication date

9 March 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

5 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

page(s)

435-445

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271

5 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

The Genetic Evolution of Melanoma from Precursor Lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

NRAS mutation status is an independent prognostic factor in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Genomic Classification of Cutaneous Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Improving Prospects for Targeting RAS.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Improved overall survival in melanoma with combined dabrafenib and trametinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Systemic treatment for BRAF-mutant melanoma: where do we go next?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

MDM4 is a key therapeutic target in cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930180-8

7 January 2021

10.1016/S1470-2045(17)30180-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28284557%20AND%20SRC:MED&resulttype=core&format=json